The Potential for microRNA Therapeutics and Clinical Research

Hanna, Johora; Hossain, Gazi S.; Kocerha, Jannet

doi:10.3389/fgene.2019.00478

Cited by 619 publications

(477 citation statements)

References 55 publications

Supporting

Mentioning

414

Contrasting

Unclassified

Order By: Relevance

“…Therefore, the miRNAs miR-26a-5p, miR-27a-3p, and miR-221-3p may provide a tool for miRNA binding prediction [40][41][42][43] . Moreover, an implementation of miRNAs (or antogomiRs) has been suggested as novel therapeutic option 44 and the here presented CREB1-specific miRNAs may be of interest for those approaches.…”

Section: Discussionmentioning

confidence: 99%

CREB1 is affected by the microRNAs miR-22-3p, miR-26a-5p, miR-27a-3p, and miR-221-3p and correlates with adverse clinicopathological features in renal cell carcinoma

Friedrich

Heimer

Stoehr

et al. 2020

Sci Rep

View full text Add to dashboard Cite

The transcription factor cAMP response element-binding protein (CREB1) has been shown to be involved in diverse biological pathways including the regulation of cell proliferation, apoptosis, cell cycle progression, and metastasis. In this context, aberrant expression of CREB1 and the functional consequences are well investigated in a number of hematopoietic and solid tumors. However, CREB1 expression and underlying control mechanisms are only poorly analyzed in renal cell carcinoma (RCC). The present study confirmed a deregulation of CREB1 protein in the clear cell type of RCC (ccRCC) and analysis of in-house ccRCC cell lines suggested a post-transcriptional control. The combination of miRNA enrichment assay, in silico analysis and molecular biological approaches revealed four novel CREB1-regulating miRNAs, namely miR-22-3p, miR-26a-5p, miR-27a-3p, and miR-221-3p. Categorizing RCC samples as CREB1 negative or positive, respectively, the expression of these miRNAs was found to be inversely correlated with CREB1 protein levels. Analyzing 453 consecutive RCC tumors by immunohistochemistry, weakly negative, but significant correlations of CREB1 with tumor stage and grade, vascular invasion (V1) and lymphovascular invasion (L1) were found. In this respect, ccRCC might differ from other solid tumors like esophageal squamous-cell carcinoma or glioma.Renal cell carcinoma (RCC) is a kidney cancer originating in the lining of proximal renal tubular epithelial cells and can be histologically subtyped into clear cell type (ccRCC, 75%), papillary (pRCC, 13-15%), chromophobe type (chRCC, 5%), and several rare subtypes 1,2 . Globally, RCC is listed as the sixth most frequently diagnosed form of cancer in men and the tenth in women, with highest rates described in North America and the Czech Republic 3,4 . Noteworthy, RCC incidence was shown to be increasing and frequently accompanied by several risk factors including smoking, hypertension, obesity, chronic analgesic use, and diabetes 5,6 . Early treatment options for RCC are quite limited and usually involve partial or complete resection of the affected kidney(s) 7 since this type of tumor is considerably resistant to chemotherapy and radiotherapy 8 . However, immunotherapy as well as biologic or targeted therapy has shown to be an efficient option for RCC treatment 9 . Thus, it is important to characterize molecular targets responsible for the formation and development of this disease. Probably best analyzed is the alteration of the tumor suppressive Von Hippel-Lindau (VHL) gene that has a crucial value in the origin and development of ccRCC and can be found to be affected in up to 90% of all ccRCC cases 10 . Situated in a complex pathway, VHL is ultimately responsible for the regulation of the transcription factors hypoxia-inducible factor 1 alpha and 2 alpha (HIF1A, HIF2A) 11,12 . The deregulation of HIF1A and HIF2A results in the up-regulation of various growth factors like vascular endothelial growth factor (VEGF), platelet-derived growth factor beta

show abstract

Section: Discussionmentioning

confidence: 99%

CREB1 is affected by the microRNAs miR-22-3p, miR-26a-5p, miR-27a-3p, and miR-221-3p and correlates with adverse clinicopathological features in renal cell carcinoma

Friedrich

Heimer

Stoehr

et al. 2020

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Moreover, miR-21 has been demonstrated to be an important biomarker of poor prognosis in several cancer types (Yan et al, 2008;Zhou et al, 2014;Arantes et al, 2017;Labib et al, 2017). For this reasons miR-21 represents one of the actionable miRNAs for novel therapeutic strategies and it is considered a robust biomarker to be implemented in clinical practice (Bonneau et al, 2019;Hanna et al, 2019).…”

Section: Micrornas As Potential Cancer Biomarkers In Tissues and In Bmentioning

confidence: 99%

Non-coding RNAs as Putative Biomarkers of Cancer-Associated Cachexia

Donzelli¹,

Farneti

Marucci

et al. 2020

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

“…They bind to partly complementary sequences present on the 3'‐UTRs (3'‐untranslated regions) of their cognate target genes and induce mRNA degradation or inhibit translation . In the human genome, more than 2500 miRNAs have been identified, which potentially regulate > 50% of all human protein‐coding gene expressions . A common trait of human malignancies, including glioma, is the aberrant expression of miRNAs which have been shown to regulate key pathological processes, such as cell angiogenesis, EMT (epithelial‐mesenchymal transition), metastasis, proliferation and apoptosis .…”

Section: Introductionmentioning

confidence: 99%

miR‐1254 inhibits progression of glioma in vivo and in vitro by targeting CSF‐1

Kong

Cao

2020

J Cellular Molecular Medi

View full text Add to dashboard Cite

The role of miRNAs (microRNAs) has been implicated in glioma initiation and progression, although the inherent biochemical mechanisms still remain to be unravelled. This study strived to evaluate the association between CSF‐1 and miR‐1254 and their effect on advancement of glioma cells. The levels of miR‐1254 in glioma cells and tissues were determined by real‐time RT‐PCR. Proliferation, apoptosis and cell cycle arrest, invasion and migration, were assessed by CCK‐8 assay, colony formation assay, flow cytometry, transwell assay and wound‐healing assay, respectively. The targeted relationship between miR‐1254 and CSF‐1 was confirmed by dual‐luciferase reporter assay. The effects of CSF‐1 on cellular functions were also assessed. The in vivo effect of miR‐1254 on the formation of a tumour was explored by using the mouse xenograft model. We found in both glioma tissues and glioma cells, the down‐regulated expressions of miR‐1254 while that of CSF‐1 was abnormally higher than normal level. The target relationship between CSF‐1 and miR‐1254 was validated by dual‐luciferase reporter assay. The CSF‐1 down‐regulation or miR‐1254 overexpression impeded the invasion, proliferation and migratory ability of U251 and U87 glioma cells, concurrently occluded the cell cycle and induced cell apoptosis. Moreover, in vivo tumour development was repressed due to miR‐1254 overexpression. Thus, CSF‐1 is targeted directly by miR‐1254, and the miR‐1254/CSF‐1 axis may be a potential diagnostic target for malignant glioma.

show abstract

The Potential for microRNA Therapeutics and Clinical Research

Cited by 619 publications

References 55 publications

CREB1 is affected by the microRNAs miR-22-3p, miR-26a-5p, miR-27a-3p, and miR-221-3p and correlates with adverse clinicopathological features in renal cell carcinoma

CREB1 is affected by the microRNAs miR-22-3p, miR-26a-5p, miR-27a-3p, and miR-221-3p and correlates with adverse clinicopathological features in renal cell carcinoma

Non-coding RNAs as Putative Biomarkers of Cancer-Associated Cachexia

miR‐1254 inhibits progression of glioma in vivo and in vitro by targeting CSF‐1

Contact Info

Product

Resources

About